Table II.
Atazanavir Pharmacokinetics with and Without Gastric pH Modulators
| Geometric Mean Ratios (90% CIs) | ||||||
|---|---|---|---|---|---|---|
| PK Parameter | ATV/RTV (Treatment A) |
ATV/RTV + RAB (Treatment B) |
ATV/RTV + RAB + BHCl (Treatment C) |
B vs A | C vs B | C vs A |
| Cmax (ng/mL) | 2,920 ± 917 | 933 ± 545 | 1,270 ± 524 | 0.291 (0.183-0.462) | 1.44 (0.909-2.29) | 0.420 (0.265-0.666) |
| AUC0-last (ng*hr/mL) | 235,000 ± 6,690 | 7,410 ± 3,580 | 10,100 ± 3,790 | 0.300 (0.206-0.439) | 1.41 (0.967-2.06) | 0.424 (0.290-0.620) |
| Tmax (hr) | 3.0 (2.0-4.0) | 3.0 (2.0-3.0) | 3.0 ± (1.5-6.0) | N/A | N/A | N/A |
Pharmacokinetic parameter data presented as mean ± SD. Tmax is expressed as median (range). CI, confidence interval; PK, pharmacokinetic; ATV, atazanavir; RTV, ritonavir; RAB, rabeprazole; BHCl, betaine hydrochloride; Cmax, maximum plasma concentration; Tmax, time to maximum plasma concentration; AUC0-last, area under the plasma concentration-time curve from time zero to 22 hours.